These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16305446)

  • 1. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology.
    Omidi Y; Barar J; Akhtar S
    Curr Drug Deliv; 2005 Oct; 2(4):429-41. PubMed ID: 16305446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells.
    Omidi Y; Hollins AJ; Benboubetra M; Drayton R; Benter IF; Akhtar S
    J Drug Target; 2003 Jul; 11(6):311-23. PubMed ID: 14668052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.
    Akhtar S
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1347-62. PubMed ID: 20929276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes.
    Nguyen LT; Atobe K; Barichello JM; Ishida T; Kiwada H
    Biol Pharm Bull; 2007 Apr; 30(4):751-7. PubMed ID: 17409515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent patents in cationic lipid carriers for delivery of nucleic acids.
    Koynova R; Tenchov B
    Recent Pat DNA Gene Seq; 2011 Apr; 5(1):8-27. PubMed ID: 21288191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells.
    Omidi Y; Barar J; Heidari HR; Ahmadian S; Yazdi HA; Akhtar S
    Toxicol Mech Methods; 2008; 18(4):369-78. PubMed ID: 20020904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic lipid vectors for plasmid DNA delivery.
    Hirko A; Tang F; Hughes JA
    Curr Med Chem; 2003 Jul; 10(14):1185-93. PubMed ID: 12678793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of current delivery systems in cancer gene therapy.
    El-Aneed A
    J Control Release; 2004 Jan; 94(1):1-14. PubMed ID: 14684267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development and application of glycosylated particulate carriers for delivery of nucleic acid medicine].
    Kawakami S
    Yakugaku Zasshi; 2008 Dec; 128(12):1743-9. PubMed ID: 19043293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic lipids in gene delivery: principles, vector design and therapeutical applications.
    Ilies MA; Seitz WA; Balaban AT
    Curr Pharm Des; 2002; 8(27):2441-73. PubMed ID: 12369942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.
    Filion MC; Phillips NC
    Biochim Biophys Acta; 1997 Oct; 1329(2):345-56. PubMed ID: 9371426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy.
    Miller AD
    Curr Med Chem; 2003 Jul; 10(14):1195-211. PubMed ID: 12678794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current developments in gene transfection agents.
    Azzam T; Domb AJ
    Curr Drug Deliv; 2004 Apr; 1(2):165-93. PubMed ID: 16305382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.
    Audouy SA; de Leij LF; Hoekstra D; Molema G
    Pharm Res; 2002 Nov; 19(11):1599-605. PubMed ID: 12458664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes.
    Birchall JC; Marichal C; Campbell L; Alwan A; Hadgraft J; Gumbleton M
    Int J Pharm; 2000 Mar; 197(1-2):233-8. PubMed ID: 10704810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
    Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
    J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution.
    O'Mahony AM; Godinho BM; Cryan JF; O'Driscoll CM
    J Pharm Sci; 2013 Oct; 102(10):3469-84. PubMed ID: 23893329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.